BANU K ARUN to Aged
This is a "connection" page, showing publications BANU K ARUN has written about Aged.
Connection Strength
0.848
-
Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prev Res (Phila). 2020 09; 13(9):795-802.
Score: 0.029
-
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
Score: 0.026
-
Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018 06; 7(6):2718-2726.
Score: 0.025
-
Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.
Score: 0.025
-
Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018 02 06; 18(1):152.
Score: 0.025
-
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306.
Score: 0.025
-
BRCA mutations in women with inflammatory breast cancer. Cancer. 2018 02 01; 124(3):466-474.
Score: 0.024
-
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma. Clin Oncol (R Coll Radiol). 2017 Jun; 29(6):335-343.
Score: 0.023
-
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77.
Score: 0.022
-
Service Delivery Model and Experiences in a Cancer Genetics Clinic for an Underserved Population. J Health Care Poor Underserved. 2015 Aug; 26(3):784-91.
Score: 0.021
-
Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients. Breast J. 2013 Jul-Aug; 19(4):431-4.
Score: 0.018
-
USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J. 2013 Jan-Feb; 19(1):10-7.
Score: 0.017
-
Genotype in BRCA-associated breast cancers. Breast J. 2013 Jan-Feb; 19(1):87-91.
Score: 0.017
-
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82.
Score: 0.016
-
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
Score: 0.016
-
Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012 Jan 15; 118(2):321-5.
Score: 0.016
-
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.
Score: 0.016
-
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53.
Score: 0.016
-
Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
Score: 0.016
-
Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011 Sep 01; 117(17):3900-7.
Score: 0.015
-
Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011 Mar-Apr; 17(2):210-2.
Score: 0.015
-
Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest. 2010 Jun; 28(5):554-9.
Score: 0.015
-
Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009 Feb 15; 115(4):725-30.
Score: 0.013
-
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7.
Score: 0.013
-
Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008 Jan-Feb; 14(1):62-8.
Score: 0.012
-
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 2007 Oct 10; 25(29):4635-41.
Score: 0.012
-
Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res. 2007 Aug 15; 13(16):4943-8.
Score: 0.012
-
Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol. 2006 May; 19(5):622-9.
Score: 0.011
-
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
Score: 0.010
-
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer. 2024 Aug 16; 24(1):1016.
Score: 0.010
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
Score: 0.010
-
Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.
Score: 0.009
-
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.
Score: 0.008
-
Endothelin converting enzyme-1 expression in endometrial adenocarcinomas. Cancer Invest. 2001; 19(8):779-82.
Score: 0.008
-
Should abbreviated breast MRI be compliant with American College of Radiology requirements for MRI accreditation? Magn Reson Imaging. 2020 10; 72:87-94.
Score: 0.007
-
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 05 10; 38(14):1539-1548.
Score: 0.007
-
Helical Radiotherapy in Early Laryngeal Cancers Could Lead to Excess Local Recurrence: Lessons From a Phase II Prospective Study. Clin Oncol (R Coll Radiol). 2020 02; 32(2):e67-e75.
Score: 0.007
-
A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer. Clin Oncol (R Coll Radiol). 2020 02; 32(2):e39-e45.
Score: 0.007
-
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 12; 76(6):831-842.
Score: 0.007
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
Score: 0.007
-
Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer. Br J Radiol. 2019 Mar; 92(1095):20180928.
Score: 0.007
-
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 11 01; 36(31):3134-3143.
Score: 0.006
-
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
Score: 0.006
-
Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. Indian J Cancer. 2018 Apr-Jun; 55(2):125-133.
Score: 0.006
-
Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
Score: 0.006
-
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr Canc Netw. 2017 06; 15(6):797-803.
Score: 0.006
-
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076.
Score: 0.006
-
Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Support Care Cancer. 2017 07; 25(7):2103-2109.
Score: 0.006
-
Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016 Dec 06; 7(49):80465-80481.
Score: 0.006
-
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist. 2016 07; 21(7):869-74.
Score: 0.006
-
Differences in quality of life between American and Chinese breast cancer survivors. Support Care Cancer. 2016 09; 24(9):3775-82.
Score: 0.005
-
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
Score: 0.005
-
BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7.
Score: 0.005
-
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
Score: 0.005
-
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jan 15; 121(2):269-75.
Score: 0.005
-
Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer. 2014 Jun; 13(2):291-9.
Score: 0.005
-
Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology. 2014 Nov; 23(11):1220-8.
Score: 0.005
-
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
Score: 0.005
-
Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet. 2015 Jun; 28(3):272-82.
Score: 0.005
-
Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol. 2014 Apr 01; 32(10):1058-65.
Score: 0.005
-
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64.
Score: 0.005
-
Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology. 2013 Oct; 22(10):2354-63.
Score: 0.004
-
The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013; 18(5):493-500.
Score: 0.004
-
Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013 Apr; 20(4):1267-74.
Score: 0.004
-
Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8.
Score: 0.004
-
Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
Score: 0.004
-
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
Score: 0.004
-
Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction. Cancer Prev Res (Phila). 2011 Nov; 4(11):1852-62.
Score: 0.004
-
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011 Oct; 18(10):2873-8.
Score: 0.004
-
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
Score: 0.004
-
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
Score: 0.004
-
External qigong therapy for women with breast cancer prior to surgery. Integr Cancer Ther. 2010 Dec; 9(4):348-53.
Score: 0.004
-
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
Score: 0.004
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):235-44.
Score: 0.004
-
A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb; 120(1):111-8.
Score: 0.004
-
The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat. 2010 Jul; 122(1):243-9.
Score: 0.004
-
Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol. 2009 Sep; 46(15):3037-49.
Score: 0.003
-
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1139-48.
Score: 0.003
-
Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 01; 115(5):962-71.
Score: 0.003
-
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.
Score: 0.003
-
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer. 2008 Jul 08; 99(1):68-71.
Score: 0.003
-
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008 Apr 14; 8:101.
Score: 0.003
-
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 01; 112(7):1455-61.
Score: 0.003
-
Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 01; 107(7):1440-7.
Score: 0.003
-
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006 Sep 15; 107(6):1348-54.
Score: 0.003
-
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer. 2006 Sep 01; 107(5):935-44.
Score: 0.003
-
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
Score: 0.003
-
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4274-82.
Score: 0.003
-
Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006 Jan 20; 24(3):354-60.
Score: 0.003
-
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005 Aug 01; 11(15):5401-9.
Score: 0.003
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
Score: 0.003
-
Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
Score: 0.002
-
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
Score: 0.002
-
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102.
Score: 0.002
-
Should mammographic screening be done in primary ovarian cancer?: A case control study in Turkish women. Med Oncol. 2004; 21(2):139-43.
Score: 0.002
-
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 15; 21(18):3454-61.
Score: 0.002
-
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 01; 21(17):3249-54.
Score: 0.002
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.002
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 01; 20(7):1800-8.
Score: 0.002
-
Serum erythropoietin level in anemic cancer patients. Med Oncol. 2000 Feb; 17(1):29-34.
Score: 0.002